4 unchanged sentences
INDEX TO EXHIBITS
−Removed: Certificate of Amendment to the Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc., filed with the Secretary of State of the State of Nevada (incorporated by reference to exhibit 3.1 of the Form 8-K filed May 3, 2024)
−Removed: Certificate of Amendment to the Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc., filed with the Secretary of State of the State of Nevada related to reverse split (incorporated by reference to exhibit 3.1 of the Form 8-K filed June 5, 2024)
−Removed: of Common Warrant issued in June 14, 2024 offering (incorporated
−Removed: by reference to exhibit 4.2 of the Form 8-K filed June 14, 2024)
−Removed: Form of Pre-Funded Warrant issued in June 14, 2024 offering (incorporated by reference to exhibit 4.1 of the Form 8-K filed June 14, 2024)
−Removed: of Common Warrant issued in June 26, 2024 offering (incorporated
−Removed: by reference to exhibit 4.1 of the Form 8-K filed June 26, 2024)
−Removed: of Common Warrant issued in July 3, 2024 offering (incorporated
−Removed: by reference to exhibit 4.1 of the Form 8-K filed July 3, 2024)
−Removed: Financial Advisory Agreement dated June 14, 2024 by and among CNS Pharmaceuticals, Inc., A.G.P./Alliance Global Partners (incorporated by reference to exhibit 10.2 of the Form 8-K filed June 14, 2024)
−Removed: Form of Securities Purchase Agreement (incorporated by reference to exhibit 10.1 of the Form 8-K filed June 14, 2024)
−Removed: CNS Pharmaceuticals, Inc.
−Removed: 2020 Equity Plan (as amended April 30, 2024) (incorporated by reference to exhibit 10.1 of the Form 8-K filed May 3, 2024)
−Removed: Financial Advisory Agreement dated June 26, 2024 by and among CNS Pharmaceuticals, Inc., A.G.P./Alliance Global Partners (incorporated by reference to exhibit 10.2 of the Form 8-K filed June 26, 2024)
−Removed: Form of Securities Purchase Agreement (incorporated by reference to exhibit 10.1 of the Form 8-K filed June 26, 2024)
+Added: Form of Common Warrant issued in July 3, 2024 offering (incorporated by reference to exhibit 4.1 of the Form 8-K filed July 3, 2024)
+Added: Form of Pre-Funded Warrant (incorporated by reference to exhibit 4.1 of the Form 8-K filed October 24, 2024)
Financial Advisory Agreement dated July 3, 2024 by and among CNS Pharmaceuticals, Inc., A.G.P./Alliance Global Partners (incorporated by reference to exhibit 10.2 of the Form 8-K filed June 26, 2024)
9 unchanged sentences
(incorporated by reference to exhibit 10.2 of the Form 8-K filed July 30, 2024)
+Added: Placement Agency Agreement dated October 23, 2024, between CNS Pharmaceuticals, Inc.
+Added: and A.G.P./Alliance Global Partners (incorporated by reference to exhibit 1.1 of the Form 8-K filed October 24, 2024)
+Added: Form of Securities Purchase
+Added: Agreement (incorporated by reference to exhibit 10.1 of the Form 8-K filed October 24, 2024)
Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
23 unchanged sentences
Chief Executive Officer and Director
−Removed: August 14, 2024
+Added: November 14, 2024
(principal executive officer)
1 unchanged sentence
Chief Financial Officer
−Removed: August 14, 2024
+Added: November 14, 2024
Christopher Downs
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.